About Symbiomix Therapeutics
Symbiomix Therapeutics is a company based in Newark (United States) founded in 2012 was acquired by Lupin in October 2017.. Symbiomix Therapeutics has raised $66.55 million across 4 funding rounds from investors including Lupin, Square 1 Bank and Orbimed. Symbiomix Therapeutics operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and SpyBiotech, among others.
- Headquarter Newark, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Symbiomix Therapeutics
Symbiomix Therapeutics has successfully raised a total of $66.55M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(09 Jul 2014)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2018 | Amount | Series B - Symbiomix Therapeutics | Valuation |
investors |
|
| May, 2016 | Amount | Series A - Symbiomix Therapeutics | Valuation |
investors |
|
| May, 2015 | Amount | Series A - Symbiomix Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Symbiomix Therapeutics
Symbiomix Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Lupin, Square 1 Bank and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and global platform support for startups.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Symbiomix Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Symbiomix Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Symbiomix Therapeutics Comparisons
Competitors of Symbiomix Therapeutics
Symbiomix Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and SpyBiotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Symbiomix Therapeutics
Frequently Asked Questions about Symbiomix Therapeutics
When was Symbiomix Therapeutics founded?
Symbiomix Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Where is Symbiomix Therapeutics located?
Symbiomix Therapeutics is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Is Symbiomix Therapeutics a funded company?
Symbiomix Therapeutics is a funded company, having raised a total of $66.55M across 4 funding rounds to date. The company's 1st funding round was a Series A of $41M, raised on Jul 09, 2014.
What does Symbiomix Therapeutics do?
Symbiomix Therapeutics was founded in 2012 in Newark, United States, within the biopharmaceutical sector focused on womens health. Operations center on developing treatments for gynecological infections, including bacterial vaginosis. The lead product, Solosec, an oral granule antibiotic, received FDA approval for single-dose BV treatment and QIDP status with 10-year exclusivity. The company was acquired by Lupins American arm in October 2017.
Who are the top competitors of Symbiomix Therapeutics?
Symbiomix Therapeutics's top competitors include Insmed, MaaT Pharma and Basilea.
Who are Symbiomix Therapeutics's investors?
Symbiomix Therapeutics has 6 investors. Key investors include Lupin, Square 1 Bank, Orbimed, Eight Roads Ventures, and HBM Partners.